Oryzon Genomics S.A.
MCE ORY.MC
Oryzon Genomics S.A. Price to Earnings Ratio (P/E) on January 14, 2025: -26.45
-
Oryzon Genomics S.A. 52-week high Price to Earnings Ratio (P/E) is -24.88 on December 31, 2024, which is 5.96% above the current Price to Earnings Ratio (P/E).
-
Oryzon Genomics S.A. 52-week low Price to Earnings Ratio (P/E) is -38.76 on April 08, 2024, which is -46.53% below the current Price to Earnings Ratio (P/E).
-
Oryzon Genomics S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is -33.44.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Carlos Manuel Buesa Arjol |
| IPO Date | Dec. 14, 2015 |
| Location | Spain |
| Headquarters | Sant Ferran 74 |
| Employees | 46 |
| Sector | Health Care |
| Industries | |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email